This event is in association with the ASH 2025 Annual Meeting.
Meeting Objectives:
-
-
Describe key challenges and evolving strategies in ensuring continuity of care for patients with relapsed/refractory multiple myeloma (R/R MM) receiving bispecific antibody therapies during transitions between academic and community settings.
-
Evaluate real-world patient cases to assess the factors that are considered in optimizing the selection and sequencing of therapies for patients with R/R MM, including clinical trial data, updated guidelines, dosing frequency, toxicities, cost, and REMS requirements.
-
Discuss the gaps in infrastructure and education that community clinics face in operationalizing and administering bispecific antibody therapies, as well as in managing patients with R/R MM.
-
Share This Event